[Vaccine-manufacturing] Politico: India’s Serum Institute to make Russia’s Sputnik V vaccine
thiru at keionline.org
Tue Jul 13 02:43:49 PDT 2021
India’s Serum Institute to make Russia’s Sputnik V vaccine
The goal is to manufacture 300 million doses of the adenoviral vaccine a
BY CARLO MARTUSCELLI
July 13, 2021 10:49 am
India's Serum Institute has entered into a partnership to manufacture doses
of Russia's Sputnik V coronavirus vaccine, Sputnik's government-sponsored
backer announced Tuesday.
The Russian Direct Investment Fund, the sovereign wealth fund that's in
charge of promoting the shot abroad, said that production is slated to
start in September, with the aim to manufacture 300 million doses of the
adenoviral vaccine a year.
Speaking to journalists, RDIF's chief executive Kirill Dmitriev said
India's drug regulator has approved the import of the necessary ingredients
to start production.
The Serum Institute is the world's largest vaccine producer and has been
making COVISHIELD, its licensed version of the Oxford/AstraZeneca jab.
Technology transfer between the Sputnik team and the Serum Institute is
already advanced and has been ongoing since before the announcement,
The shot is already approved for use in India, and RDIF has signed
agreements with other Indian manufacturers to make enough doses for more
than 425 million people a year.
Dmitriev said that Sputnik doses produced in virus-battered India would
"first go to the Indian market," but that the RDIF would also look into
exporting shots. Asked about the possibility of "mixing doses" with the
Oxford/AstraZeneca vaccine being produced in the country, he pointed to an
ongoing clinical study in Azerbaijan looking into combining the different
vaccines, with results expected by the end of July.
Sputnik is being used by countries all over the world, including in South
America and Asia, but it's also been dogged by claims of lack of
transparency and problems with the quality of the data. The most recent
snag, as reported by Reuters, is that Sputnik's authorization with the
Europe's drug regulator is stuck. According to Reuters, the European
Medicines Agency hasn't received enough information to make a decision on
whether to approve the vaccine, citing a lack of manufacturing data in
Dmitriev called the agreement "an example of a very key partnership between
different countries such as Russia and India."
Knowledge Ecology International
41 22 791 6727
thiru at keionline.org
More information about the Vaccine-manufacturing